ARCHIVE

US Court Orders Actelion to Pay Damages to Asahi Kasei Pharma for Stopping Fasudil's Development

August 29, 2011
Asahi Kasei Pharma has announced that the Superior Court of California, County of San Mateo, ordered Actelion of Switzerland on August 18 to pay US$516.6 million to Asahi Kasei Pharma. Asahi Kasei Pharma has been demanding damages claiming that Actelion…

To read the full story

ARCHIVE

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Takashi Ebisawa

Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…

By Philip Carrigan

The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…